BioSpace News Archive

Analysis supports ensifentrine’s efficacy in COPD as monotherapy and on top of standard of care treatment in patients who remain symptomatic Six abstracts accepted demonstrating ensifentrine’s potential across treatment settings and formulations LONDON, May 01, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that six abstracts presenting clinically relevant findi

Study by CHOP researchers finds debilitating lawnmower injuries continue to occur throughout U.S., despite improvements in lawnmower design

Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced it has expanded its presence in Iowa through its partnership with John H. Wollner, MD..

Enzychem Lifesciences , a clinical-stage biotherapeutics company engaged in the discovery and development of innovative medicines focused on the inflammation pathway, today announced that preclinical research involving their lead compound EC-18 (PLAG), and its activity in gouty arthritis have been published in the peer-reviewed journal

ALJ recommends exclusion and cease and desist order against infringing 3Shape products

- Janssen’s DARZALEX FASPRO™ is a subcutaneous co-formulation of DARZALEX® and Halozyme’s ENHANZE® technology - - Innovative, fixed-dose formulation demonstrates consistent efficacy to intravenous DARZALEX® with lower rate of infusion-related reactions - - Can be administered in three to five minutes compared to multi-hour infusions with intravenous DARZALEX® -

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab

Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the first quarter ended March 31, 2020 and provided an update on its strategic process.

Immunomedics, Inc., a leading biopharmaceutical company in the area of antibody-drug conjugates, announced the closing of its previously announced underwritten public offering of common stock.

Recro Pharma, Inc. announced that due to the emerging health impact of the coronavirus pandemic, the Company has changed the location of its 2020 Annual Meeting of Stockholders to its corporate headquarters at 490 Lapp Road, Malvern, Pennsylvania 19355.